ADXN - addextherapeutics.com Forward P/E Multiple
Addex Therapeutics is optimizing costs by utilizing a virtual drug development model and European contractors. The company's consensus forward P/E clearly demonstrates market expectations, where 0.00 serves as the current metric level. However, geopolitical tensions and logistics disruptions are hindering clinical trials. Currently, financial stability relies on partner payments, as the company lacks its own commercial products.
Financial and market metric breakdowns for Addex (ADXN)
- stock quotes and analyst forecast:
- market capitalization statistics:
- book capitalization information:
- business debt structure and liquidity details:
Total Debt to Equity Ratio Addex Therapeutics|ADXN - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio Addex Therapeutics|ADXN - Company Cumulative Indebtedness|Debts to Book Capitalization Addex Therapeutics Ltd.|ADXN - Company Long-Term Loans and Borrowings|Company Short-Term Debts Addex Therapeutics|Quick Liquidity addextherapeutics.com
- earnings and market ratios statistics:
ADXN - Final Profit|Projected Future Earnings Addex Therapeutics|ADXN - P/E Multiple|Future Price to Earnings Addex Therapeutics, Ltd.|ADXN - Market Cap to Earnings and Growth Ratio|EV/EBITDA Multiple Addex Therapeutics Ltd.|ADXN - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Addex Therapeutics|ADXN - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months addextherapeutics.com|ADXN - Net earnings per one share growth for the current year|Earnings growth forecast for next year Addex Therapeutics
Summary company analysis:Addex Therapeutics Ltd
Forward P/E assesses asset value through the ratio of current price to projected earnings for the following year, allowing for the determination of the premium paid for future income. Analyzing the projected P/E multiple of Addex Therapeutics (ADXN) at 0.00, an investor identifies risks where a chronic deficit in operating cash flow and a reliance on grants render this calculation purely speculative.
Direct competitors
Forward P/E Multiple BIIB|Neurocrine - Price to Future Earnings Ratio|Forward P/E Multiple RGC (Regencell)|AXSM: Price to Future Earnings Ratio|ACADIA Pharmaceuticals - Forward P/E Multiple|Projected Price to Earnings Ratio xenon-pharma.com|VKTX (Viking Therapeutics, Inc.) - Projected Price to Earnings|Price to Future Earnings Ratio SUPN|Projected Price to Earnings CPRX|DNLI: Future Price to Earnings Multiple|Projected Price to Earnings HRMY (Harmony Biosciences)|Market Cap to Future Earnings Ratio BHVN|Forward P/E Multiple AMLX (Amylyx Pharmaceuticals, Inc.)|Future Price to Earnings Multiple TRVI|Praxis Medicines - Forward P/E Multiple|Projected Price to Earnings Ratio Anavex Life Sciences Corp|CeriBell, Inc. (CBLL) - Future Price to Earnings|Prothena - Future Price to Earnings Multiple|ALEC (Alector Inc.) - Forward P/E Multiple|Forward P/E Multiple Annexon Biosciences|Future Price to Earnings Omeros Corporation (OMER)|NGNE: Price to Expected Earnings Ratio|Forward P/E Multiple ACIU (AC Immune)|voyagertherapeutics.com (VYGR) - Projected Price to Earnings Ratio|NMRA: Projected Price to Earnings|SCLX - Forward P/E Multiple|TVGN (Tevogen Bio Holdings, Inc.) - Projected Price to Earnings|ACOG: Market Cap to Future Earnings Ratio|CGTX (Cognition Therapeutics) - Forward P/E Multiple|inhibikase.com (IKT) - Market Cap to Projected Earnings|Forward P/E Multiple SAVA|Projected Price to Earnings assertiotx.com ASRT|Future Price to Earnings Coya Therapeutics COYA|Market Cap to Projected Earnings VistaGen Therapeutics, Inc. (VTGN)|Ovid Rx - Forward P/E Multiple|ABOS - Forward P/E Multiple|CRVO: Forward P/E Multiple|Price to Future Earnings Ratio ATHE|Projected Price to Earnings CLNN|Price to Future Earnings Ratio PEPG (PepGen Corp)|Future Price to Earnings Jupiter Neurosciences Inc (JUNS)|relmada.com - Price to Future Earnings Ratio|Future Price to Earnings Annovis Bio ANVS|GRCE: Price to Future Earnings Ratio|Firefly Neuroscience Inc - Forward P/E Multiple|Projected Price to Earnings Ratio Klotho Neurosciences Inc|NRSN (neurosense-tx.com) - Projected Price to Earnings|revivapharma.com (RVPH) - Forward P/E Multiple|Future Price to Earnings MetaVia Inc.|NRXS: Future Price to Earnings Multiple|Future Price to Earnings Helius Medical (HSDT)|PASG - Projected Price to Earnings Ratio|Forward P/E Multiple NEUP (Neuphoria Therapeutics)|Forward P/E Multiple minervaneurosciences.com NERV|Athira Pharma - Forward P/E Multiple|ALZN (Alzamend Neuro, Inc.) - Price to Future Earnings Ratio|CYCN: Forward P/E Multiple|Price to Future Earnings Ratio PTIX|KTTA (Pasithea Therapeutics Corp) - Forward P/E Multiple|Projected Price to Earnings Ratio Cortigent Medical CRGT|Projected Price to Earnings ATXI (Avenue Therapeutics, Inc.)|Brainstorm Cell Therapeutics Inc. - Price to Future Earnings Ratio|Cara Therapeutics, Inc - Projected Price to Earnings|Future Price to Earnings Multiple CHRO|ELYM: Projected Price to Earnings|Intra-Cellular Therapies - Market Cap to Future Earnings Ratio|LBPH: Forward P/E Multiple|Marinus Pharmaceuticals Inc - Future Price to Earnings Multiple|NKGN (NKGen) - Forward P/E Multiple|Projected Price to Earnings Ratio NeuroBo Pharma NRBO|Future Price to Earnings Sage Therapeutics, Inc. (SAGE)|SNPX (synaptogen.com) - Future Price to Earnings Multiple|Forward P/E Multiple TRVN (Trevena)|Forward P/E Multiple Vigil Neuroscience Inc. VIGL|WENA - Future Price to Earnings|Price to Expected Earnings Ratio CERE
